2025-04-01 2026-03-31 2026-03-31 false 07576566 SAFA Diagnostics Limited 2026-06-01 86900 false iso4217:GBP xbrli:pure 07576566 2025-03-31 07576566 2026-03-31 07576566 2025-04-01 2026-03-31 07576566 2024-03-31 07576566 2025-03-31 07576566 2024-04-01 2025-03-31 07576566 bus:SmallEntities 2025-04-01 2026-03-31 07576566 bus:AuditExempt-NoAccountantsReport 2025-04-01 2026-03-31 07576566 bus:FullAccounts 2025-04-01 2026-03-31 07576566 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 07576566 core:WithinOneYear 2026-03-31 07576566 core:AfterOneYear 2026-03-31 07576566 core:WithinOneYear 2025-03-31 07576566 core:AfterOneYear 2025-03-31 07576566 core:ShareCapital 2026-03-31 07576566 core:SharePremium 2026-03-31 07576566 core:RevaluationReserve 2026-03-31 07576566 core:OtherReservesSubtotal 2026-03-31 07576566 core:RetainedEarningsAccumulatedLosses 2026-03-31 07576566 core:ShareCapital 2025-03-31 07576566 core:SharePremium 2025-03-31 07576566 core:RevaluationReserve 2025-03-31 07576566 core:OtherReservesSubtotal 2025-03-31 07576566 core:RetainedEarningsAccumulatedLosses 2025-03-31 07576566 core:LandBuildings 2026-03-31 07576566 core:PlantMachinery 2026-03-31 07576566 core:Vehicles 2026-03-31 07576566 core:FurnitureFittings 2026-03-31 07576566 core:OfficeEquipment 2026-03-31 07576566 core:NetGoodwill 2026-03-31 07576566 core:IntangibleAssetsOtherThanGoodwill 2026-03-31 07576566 core:ListedExchangeTraded 2026-03-31 07576566 core:UnlistedNon-exchangeTraded 2026-03-31 07576566 core:LandBuildings 2025-03-31 07576566 core:PlantMachinery 2025-03-31 07576566 core:Vehicles 2025-03-31 07576566 core:FurnitureFittings 2025-03-31 07576566 core:OfficeEquipment 2025-03-31 07576566 core:NetGoodwill 2025-03-31 07576566 core:IntangibleAssetsOtherThanGoodwill 2025-03-31 07576566 core:ListedExchangeTraded 2025-03-31 07576566 core:UnlistedNon-exchangeTraded 2025-03-31 07576566 core:LandBuildings 2025-04-01 2026-03-31 07576566 core:PlantMachinery 2025-04-01 2026-03-31 07576566 core:Vehicles 2025-04-01 2026-03-31 07576566 core:FurnitureFittings 2025-04-01 2026-03-31 07576566 core:OfficeEquipment 2025-04-01 2026-03-31 07576566 core:NetGoodwill 2025-04-01 2026-03-31 07576566 core:IntangibleAssetsOtherThanGoodwill 2025-04-01 2026-03-31 07576566 core:ListedExchangeTraded 2025-04-01 2026-03-31 07576566 core:UnlistedNon-exchangeTraded 2025-04-01 2026-03-31 07576566 core:MoreThanFiveYears 2025-04-01 2026-03-31 07576566 core:Non-currentFinancialInstruments 2026-03-31 07576566 core:Non-currentFinancialInstruments 2025-03-31 07576566 dpl:CostSales 2025-04-01 2026-03-31 07576566 dpl:DistributionCosts 2025-04-01 2026-03-31 07576566 core:LandBuildings 2025-04-01 2026-03-31 07576566 core:PlantMachinery 2025-04-01 2026-03-31 07576566 core:Vehicles 2025-04-01 2026-03-31 07576566 core:FurnitureFittings 2025-04-01 2026-03-31 07576566 core:OfficeEquipment 2025-04-01 2026-03-31 07576566 dpl:AdministrativeExpenses 2025-04-01 2026-03-31 07576566 core:NetGoodwill 2025-04-01 2026-03-31 07576566 core:IntangibleAssetsOtherThanGoodwill 2025-04-01 2026-03-31 07576566 dpl:GroupUndertakings 2025-04-01 2026-03-31 07576566 dpl:ParticipatingInterests 2025-04-01 2026-03-31 07576566 dpl:GroupUndertakings core:ListedExchangeTraded 2025-04-01 2026-03-31 07576566 core:ListedExchangeTraded 2025-04-01 2026-03-31 07576566 dpl:GroupUndertakings core:UnlistedNon-exchangeTraded 2025-04-01 2026-03-31 07576566 core:UnlistedNon-exchangeTraded 2025-04-01 2026-03-31 07576566 dpl:CostSales 2024-04-01 2025-03-31 07576566 dpl:DistributionCosts 2024-04-01 2025-03-31 07576566 core:LandBuildings 2024-04-01 2025-03-31 07576566 core:PlantMachinery 2024-04-01 2025-03-31 07576566 core:Vehicles 2024-04-01 2025-03-31 07576566 core:FurnitureFittings 2024-04-01 2025-03-31 07576566 core:OfficeEquipment 2024-04-01 2025-03-31 07576566 dpl:AdministrativeExpenses 2024-04-01 2025-03-31 07576566 core:NetGoodwill 2024-04-01 2025-03-31 07576566 core:IntangibleAssetsOtherThanGoodwill 2024-04-01 2025-03-31 07576566 dpl:GroupUndertakings 2024-04-01 2025-03-31 07576566 dpl:ParticipatingInterests 2024-04-01 2025-03-31 07576566 dpl:GroupUndertakings core:ListedExchangeTraded 2024-04-01 2025-03-31 07576566 core:ListedExchangeTraded 2024-04-01 2025-03-31 07576566 dpl:GroupUndertakings core:UnlistedNon-exchangeTraded 2024-04-01 2025-03-31 07576566 core:UnlistedNon-exchangeTraded 2024-04-01 2025-03-31 07576566 core:NetGoodwill 2026-03-31 07576566 core:IntangibleAssetsOtherThanGoodwill 2026-03-31 07576566 core:LandBuildings 2026-03-31 07576566 core:PlantMachinery 2026-03-31 07576566 core:Vehicles 2026-03-31 07576566 core:FurnitureFittings 2026-03-31 07576566 core:OfficeEquipment 2026-03-31 07576566 core:AfterOneYear 2026-03-31 07576566 core:WithinOneYear 2026-03-31 07576566 core:ListedExchangeTraded 2026-03-31 07576566 core:UnlistedNon-exchangeTraded 2026-03-31 07576566 core:ShareCapital 2026-03-31 07576566 core:SharePremium 2026-03-31 07576566 core:RevaluationReserve 2026-03-31 07576566 core:OtherReservesSubtotal 2026-03-31 07576566 core:RetainedEarningsAccumulatedLosses 2026-03-31 07576566 core:NetGoodwill 2025-03-31 07576566 core:IntangibleAssetsOtherThanGoodwill 2025-03-31 07576566 core:LandBuildings 2025-03-31 07576566 core:PlantMachinery 2025-03-31 07576566 core:Vehicles 2025-03-31 07576566 core:FurnitureFittings 2025-03-31 07576566 core:OfficeEquipment 2025-03-31 07576566 core:AfterOneYear 2025-03-31 07576566 core:WithinOneYear 2025-03-31 07576566 core:ListedExchangeTraded 2025-03-31 07576566 core:UnlistedNon-exchangeTraded 2025-03-31 07576566 core:ShareCapital 2025-03-31 07576566 core:SharePremium 2025-03-31 07576566 core:RevaluationReserve 2025-03-31 07576566 core:OtherReservesSubtotal 2025-03-31 07576566 core:RetainedEarningsAccumulatedLosses 2025-03-31 07576566 core:NetGoodwill 2024-03-31 07576566 core:IntangibleAssetsOtherThanGoodwill 2024-03-31 07576566 core:LandBuildings 2024-03-31 07576566 core:PlantMachinery 2024-03-31 07576566 core:Vehicles 2024-03-31 07576566 core:FurnitureFittings 2024-03-31 07576566 core:OfficeEquipment 2024-03-31 07576566 core:AfterOneYear 2024-03-31 07576566 core:WithinOneYear 2024-03-31 07576566 core:ListedExchangeTraded 2024-03-31 07576566 core:UnlistedNon-exchangeTraded 2024-03-31 07576566 core:ShareCapital 2024-03-31 07576566 core:SharePremium 2024-03-31 07576566 core:RevaluationReserve 2024-03-31 07576566 core:OtherReservesSubtotal 2024-03-31 07576566 core:RetainedEarningsAccumulatedLosses 2024-03-31 07576566 core:AfterOneYear 2025-04-01 2026-03-31 07576566 core:WithinOneYear 2025-04-01 2026-03-31 07576566 core:Non-currentFinancialInstruments core:CostValuation 2025-04-01 2026-03-31 07576566 core:Non-currentFinancialInstruments core:AdditionsToInvestments 2025-04-01 2026-03-31 07576566 core:Non-currentFinancialInstruments core:RevaluationsIncreaseDecreaseInInvestments 2025-04-01 2026-03-31 07576566 core:Non-currentFinancialInstruments core:DisposalsDecreaseInInvestments 2025-04-01 2026-03-31 07576566 core:Non-currentFinancialInstruments core:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments 2025-04-01 2026-03-31 07576566 core:Non-currentFinancialInstruments core:ImpairmentLossReversalProvisionsForImpairmentInvestments 2025-04-01 2026-03-31 07576566 core:Non-currentFinancialInstruments core:AcquisitionsIncreaseInProvisionsForImpairmentInvestments 2025-04-01 2026-03-31 07576566 core:Non-currentFinancialInstruments core:DisposalsDecreaseInProvisionsForImpairmentInvestments 2025-04-01 2026-03-31 07576566 core:Non-currentFinancialInstruments core:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments 2025-04-01 2026-03-31 07576566 core:Non-currentFinancialInstruments core:CostValuation 2026-03-31 07576566 core:Non-currentFinancialInstruments core:AdditionsToInvestments 2026-03-31 07576566 core:Non-currentFinancialInstruments core:RevaluationsIncreaseDecreaseInInvestments 2026-03-31 07576566 core:Non-currentFinancialInstruments core:DisposalsDecreaseInInvestments 2026-03-31 07576566 core:Non-currentFinancialInstruments core:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments 2026-03-31 07576566 core:Non-currentFinancialInstruments core:ImpairmentLossReversalProvisionsForImpairmentInvestments 2026-03-31 07576566 core:Non-currentFinancialInstruments core:AcquisitionsIncreaseInProvisionsForImpairmentInvestments 2026-03-31 07576566 core:Non-currentFinancialInstruments core:DisposalsDecreaseInProvisionsForImpairmentInvestments 2026-03-31 07576566 core:Non-currentFinancialInstruments core:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments 2026-03-31 07576566 core:Non-currentFinancialInstruments core:CostValuation 2025-03-31 07576566 core:Non-currentFinancialInstruments core:AdditionsToInvestments 2025-03-31 07576566 core:Non-currentFinancialInstruments core:RevaluationsIncreaseDecreaseInInvestments 2025-03-31 07576566 core:Non-currentFinancialInstruments core:DisposalsDecreaseInInvestments 2025-03-31 07576566 core:Non-currentFinancialInstruments core:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments 2025-03-31 07576566 core:Non-currentFinancialInstruments core:ImpairmentLossReversalProvisionsForImpairmentInvestments 2025-03-31 07576566 core:Non-currentFinancialInstruments core:AcquisitionsIncreaseInProvisionsForImpairmentInvestments 2025-03-31 07576566 core:Non-currentFinancialInstruments core:DisposalsDecreaseInProvisionsForImpairmentInvestments 2025-03-31 07576566 core:Non-currentFinancialInstruments core:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments 2025-03-31 07576566 bus:Director1 2025-04-01 2026-03-31 07576566 bus:Director2 2025-04-01 2026-03-31

SAFA Diagnostics Limited

Registered Number
07576566
(England and Wales)

Unaudited Financial Statements for the Year ended
31 March 2026

SAFA Diagnostics Limited
Company Information
for the year from 1 April 2025 to 31 March 2026

Directors | Sandra Bode-Fallahi
| Dr Farshid Fallahi

Company Secretary | Sandra Bode-Fallahi

Registered Address | 1 Holme Farm Court
| Cumwhinton
| Carlisle
| CA4 8DS

Registered Number | 07576566 (England and Wales)

SAFA Diagnostics Limited
Statement of Financial Position
31 March 2026

| Notes | 2026 |  | 2025
--- | --- | --- | --- | ---
|  | £ |  | £ |  | £ |  | £
Fixed assets |  |  |  |  |  |  |  |
Tangible assets | 3 |  |  | 1,566 |  |  |  | 1,842
|  |  |  | 1,566 |  |  |  | 1,842
Current assets |  |  |  |  |  |  |  |
Cash at bank and on hand |  | 30,319 |  |  |  | 24,319 |  |
|  | 30,319 |  |  |  | 24,319 |  |
Creditors amounts falling due within one year | 5 | (29,622) |  |  |  | (26,122) |  |
Net current assets (liabilities) |  |  |  | 697 |  |  |  | (1,803)
Total assets less current liabilities |  |  |  | 2,263 |  |  |  | 39
Net assets |  |  |  | 2,263 |  |  |  | 39
Capital and reserves |  |  |  |  |  |  |  |
Called up share capital |  |  |  | 101 |  |  |  | 101
Profit and loss account |  |  |  | 2,162 |  |  |  | (62)
Shareholders' funds |  |  |  | 2,263 |  |  |  | 39

- The company was entitled to exemption from audit for this reporting period under section 477 of the Companies Act 2006 relating to small companies.
- The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
- The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
- These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.
- The directors have chosen to not file a copy of the company’s profit and loss account under section 444 (5A) Companies Act 2006.

The financial statements were approved and authorised for issue by the Board of Directors on 1 June 2026, and are signed on its behalf by:
Dr Farshid Fallahi Director
Sandra Bode-Fallahi Director Registered Company No. 07576566

SAFA Diagnostics Limited
Notes to the Financial Statements
for the year ended 31 March 2026

1. | Accounting policies
--- | ---

| Statutory information
--- | ---
| The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

| Basis of preparation
--- | ---
| The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).

| Functional and presentation currency
--- | ---
| The financial statements are presented in sterling and this is the functional currency of the company.

| Judgements and key sources of estimation uncertainty
--- | ---
| Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. There are no key assumptions and other sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.

| Turnover policy
--- | ---
| Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

| Foreign currency translation
--- | ---
| Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

| Current taxation
--- | ---
| Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

| Tangible fixed assets and depreciation
--- | ---
| Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

|  | Reducing balance (%)
| Plant and machinery | 15

| Trade and other debtors
--- | ---
| Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

| Cash and cash equivalents
--- | ---
| Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are disclosed separately. For the purpose of the cash flow statement, bank overdrafts form an integral part of the company's cash management and are included as a component of cash and cash equivalents.

| Trade and other creditors
--- | ---
| Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

| Government grants or assistance
--- | ---
| Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received. A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

2. | Average number of employees
--- | ---

|  | 2026 |  | 2025
| Average number of employees during the year | 2 |  | 2

3. | Tangible fixed assets
--- | ---

|  | Plant & machinery |  | Total
--- | --- | --- | --- | ---
|  | £ |  | £
| Cost or valuation
| At 01 April 25 | 9,083 |  | 9,083
| At 31 March 26 | 9,083 |  | 9,083
| Depreciation and impairment
| At 01 April 25 | 7,241 |  | 7,241
| Charge for year | 276 |  | 276
| At 31 March 26 | 7,517 |  | 7,517
| Net book value
| At 31 March 26 | 1,566 |  | 1,566
| At 31 March 25 | 1,842 |  | 1,842

4. | Impairment of tangible fixed assets
--- | ---
| A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

5. | Creditors: amounts due within one year
--- | ---

|  | 2026 |  | 2025
--- | --- | --- | --- | ---
|  | £ |  | £
| Taxation and social security | 5,469 |  | 4,334
| Other creditors | 23,373 |  | 21,008
| Accrued liabilities and deferred income | 780 |  | 780
| Total | 29,622 |  | 26,122

| Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.